证券代码：002019 证券简称：亿帆医药 公告编号：2023-061 亿帆医药股份有限公司 关于在下属子公司之间调剂担保额度及为全资子公司提供担保 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保额度调剂情况 亿帆医药股份有限公司（以下简称"公司"）于 2023 年 4 月 13 日召开的第 八届董事会第五次会议及 2023 年 6 月 2 日召开的 2022 年年度股东大会，均审 议通过了《关于公司及控股公司向金融机构申请授信额度及公司合并报表范围内 担保额度的议案》，同意公司及控股公司向各家金融机构申请总额度不超过人民 币 550,000 万元（或等值外币）的综合授信融资，申请纳入公司合并报表范围内 的公司（含本次预计担保批准期间内新设立或收购的全资和控股子公司）相互提 供担保，担保额度合计不超过人民币 500,000 万元（或等值外币），其中，对资 产负债率低于 70%的合并范围内的公司提供 490,000 万元人民币的担保总额度， 对资产负债率为 70%以上的合并范围内的公司提供 10,000 万元人民币的担保总 额度，上述担保额 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2023-059 亿帆医药股份有限公司 回购报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示: 1、亿帆医药股份有限公司（以下简称"公司"）拟使用自有资金以集中竞价 交易的方式回购公司股份用于股权激励或员工持股计划，回购股份的资金总额为 不低于人民币3,000万元（含）且不超过人民币5,000万元（含），回购价格不超 过人民币20元/股（含）。按照本次回购金额下限人民币3,000万元，回购价格上 限人民币20元/股进行测算，回购数量约为150万股，回购股份比例约占公司总股 本的0.12%；按照本次回购金额上限人民币5,000万元，回购价格上限人民币20元 /股进行测算，回购数量约为250万股，回购股份比例约占公司总股本的0.20%。 具体回购股份的数量以回购期满时实际回购的股份数量为准。回购期限为自公司 董事会审议通过本次回购方案之日起不超过12个月。 2、本次回购股份事项已经公司2023年8月29日召开的第八届董事会第九次 （临时）会议审议通过，公司独立董事对该事项发表了同意的独立意见 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2023-060 亿帆医药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）于2023年8月29日召开第八届董 事会第九次（临时）会议，审议通过了《关于回购公司股份方案的议案》，公司 拟使用自有资金以集中竞价交易的方式回购公司股份用于股权激励或员工持股 计划，回购股份的资金总额为不低于人民币3,000万元（含）且不超过人民币5,000 万元（含），回购价格不超过人民币20元/股。具体详见公司于2023年8月31日、 2023年9月2日登载于《证券日报》、《上海证券报》、《中国证券报》及巨潮资 讯网上的《关于回购公司股份方案的公告》（公告编号：2023-057）、《回购报 告书》（公告编号：2023-058）等相关公告。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等有关规定，公司回购期间应在每个月的前三个交易日内 披露截至上月末的回购进展情况，现将回购进展情况公告如下： 2023年9月 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2023-058 亿帆医药股份有限公司 关于回购股份事项前十名股东和前十名无限售条件股东持股信 息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）于2023年8月29日召开第八届董 事会第九次（临时）会议审议通过《关于回购公司股份方案的议案》。根据《公 司章程》的相关规定，本次回购股份事项无需提交公司股东大会审议。具体内容 详见公司2023年8月31日登载于《证券日报》、《上海证券报》、《中国证券报》 及 巨 潮 资 讯 网（http://www.cninfo.com.cn）上的相关公告。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，现将公司董事会公告回购股份决议的前一个 交易日（即2023年8月30日）登记在册的前十名股东和前十名无限售条件股东的 名称及持股数量、比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本的比例（%） | | --- | --- | --- | --- ...

Investment and Financial Performance - The company reported a significant increase in long-term equity investments, with initial investment costs determined based on the fair value of identifiable net assets at the acquisition date[1]. - The company utilizes the cost method for accounting long-term equity investments in subsidiaries, recognizing investment income based on declared cash dividends or profits[4]. - For equity method investments in joint ventures and associates, the company adjusts the carrying value based on its share of net income and other comprehensive income[5]. - The company confirmed that any unrealized internal transaction profits with joint ventures and associates are offset based on the proportion attributable to the company[6]. - The company’s investment properties are measured using the cost model, with subsequent expenditures capitalized when economic benefits are likely to flow in[10]. - The company’s accounting policies ensure that any loss of control over investments results in the recognition of the difference between the fair value and carrying amount in the current period's profit or loss[9]. - The company reported a significant increase in contract assets, reflecting the rights to receive consideration from customers for goods transferred or services provided[51]. - The company reported a non-recurring gain of CNY 322,816.80 mainly from the disposal of intangible assets and fixed assets during the reporting period[78]. - The company received government subsidies amounting to ¥15,108,665.85 during the reporting period, primarily related to government support for normal business operations[80]. - The company reported other operating income of ¥1,697,927.38, mainly from compensation for asset damage received during the reporting period[80]. - The company’s operating revenue for the first half of 2023 was CNY 1,944,049,304.17, representing a 9.87% increase compared to CNY 1,769,347,695.63 in the same period last year[67]. - The net profit attributable to shareholders of the listed company decreased by 32.32% to CNY 108,660,386.75 from CNY 160,560,030.39 year-on-year[67]. - The net profit after deducting non-recurring gains and losses was CNY 94,194,407.44, down 10.60% from CNY 105,358,053.27 in the previous year[67]. - The net cash flow from operating activities was CNY 153,438,550.29, a decrease of 16.52% compared to CNY 183,810,575.85 in the same period last year[67]. - Basic and diluted earnings per share were both CNY 0.09, down 30.77% from CNY 0.13 year-on-year[67]. - The weighted average return on equity was 1.20%, down from 1.86% in the previous year, a decrease of 0.66%[67]. - Total assets at the end of the reporting period were CNY 12,580,157,590.53, a slight increase of 0.29% from CNY 12,543,503,416.06 at the end of the previous year[67]. - The net assets attributable to shareholders of the listed company increased by 1.93% to CNY 8,981,727,050.21 from CNY 8,811,484,555.00 at the end of the previous year[67]. Research and Development - The company is actively engaged in research and development of new products, including the development of innovative drug formulations[60]. - Research phase expenditures are recognized as expenses, while development phase expenditures can be capitalized if specific conditions are met[48]. - The company is enhancing its marketing capabilities across domestic, European, Asia-Pacific, and emerging markets, strengthening its competitive edge in the pharmaceutical industry[94]. - The company is positioned to benefit from the ongoing health initiatives and the aging population in China, which are expected to drive demand for pharmaceutical products[90]. - The company is expanding its product offerings in the vitamin sector, focusing on diversifying its product types to mitigate the impact of price fluctuations[91]. - The company is actively advancing the commercialization process of its first self-developed I-type biological innovative drug, which has received approval from the National Medical Products Administration[112]. - The company has completed a major asset restructuring, acquiring 100% equity of Yifan Biopharmaceutical and Hefei Yifan Pharmaceutical[60]. - The company has established a robust pipeline of products under development, including innovative therapies aimed at addressing unmet medical needs[60]. - The company is one of the few Chinese enterprises that have submitted new drug applications for biological products simultaneously to the US, Europe, and China[94]. - The company is enhancing its research and development efficiency while focusing on improving drug accessibility[174]. Market and Sales Performance - The company’s proprietary pharmaceutical products (including imports) generated operating revenue of 1,030.72 million RMB, up 20.92% year-on-year[111]. - The overseas pharmaceutical business generated operating revenue of 268.31 million RMB, a 1.96% increase compared to the same period last year[114]. - The domestic pharmaceutical market achieved operating revenue of 1,178.62 million RMB, a year-on-year increase of 15.28%[118]. - The direct markets (South Korea, the Philippines, and Australia) and emerging markets achieved revenue growth of 17.90% and 163.49%, respectively[114]. - The sales of the company's major products, including recombinant human insulin injection and recombinant human growth hormone, totaled 153.84 million RMB, accounting for 72.44% of overseas sales revenue[114]. - The company successfully launched 9 new products, including two first-generic products, enhancing its domestic pharmaceutical product line[110]. - The Chinese medicine segment generated sales of ¥40,460.18 million, up 14.80% from ¥35,244.79 million in the first half of 2022[120]. - The chemical medicine segment saw a significant increase in sales, reaching ¥38,699.94 million, which is a 39.44% rise from ¥27,753.54 million year-on-year[120]. Risk Management - The company faces various risks, including research and development risks, goodwill impairment risks, exchange rate fluctuation risks, and international operation risks[26]. - The company will strengthen its overseas business risk management and emergency response plans to mitigate international operational risks[179]. - The company plans to enhance collection efforts and improve collection assessment indicators to reduce bad debt provisions[183]. - The company will closely monitor international market dynamics and foreign exchange trends to mitigate currency fluctuation risks[178]. - The company faced risks in drug research and development, including long cycles, high investment, and the uncertainty of clinical trial outcomes[174]. Environmental and Regulatory Compliance - The company has implemented measures to monitor and control pollutant emissions in compliance with various environmental laws and regulations[194]. - All construction projects of the company and its subsidiaries have passed environmental impact assessments and other environmental protection administrative approvals[198]. - The wastewater discharge from Hangzhou Xinfuh has a COD concentration of 21.5 mg/L, which is below the standard of 100 mg/L, with a total discharge of 0.073 tons[199]. - The ammonia nitrogen concentration in wastewater from Hangzhou Xinfuh is 4.10 mg/L, well below the standard of 20 mg/L, with a total discharge of 0.014 tons[199]. - The sulfur dioxide concentration in exhaust gas from Hangzhou Xinfuh is 2.5 mg/m3, significantly below the standard of 50 mg/m3, with a total discharge of 0.563 tons[199]. - The nitrogen oxides concentration in exhaust gas from Hangzhou Xinfuh is 22.5 mg/m3, below the standard of 150 mg/m3, with a total discharge of 5.068 tons[199]. - The particulate matter concentration in exhaust gas from Hangzhou Xinfuh is 1.9 mg/m3, below the standard of 20 mg/m3, with a total discharge of 0.428 tons[199]. - The volatile organic compounds concentration in exhaust gas from Hangzhou Xinfuh is 50 mg/m3, compliant with the standard of less than 60 mg/m3[199]. - The COD concentration in wastewater from Anqing Xinfuh is 31.77 mg/L, well below the standard of 500 mg/L, with a total discharge of 1.434 tons[199]. Corporate Governance and Management - The company ensures the financial report's authenticity, accuracy, and completeness, with all directors present for the board meeting[26]. - The employee stock ownership plan includes 69 employees holding a total of 7,292,100 shares, representing 0.59% of the company's total equity[188]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves[27]. - The company did not distribute cash dividends or issue bonus shares for the half-year period[187]. - The company will focus on improving drug accessibility while enhancing research and development efficiency[174]. - The company plans to enhance brand building and achieve synergy by integrating acquired companies' products and operations[175].

证券代码：002019 证券简称：亿帆医药 公告编号：2023-053 亿帆医药股份有限公司 第八届监事会第七次会议决议公告 （二）会议以 3 票同意、0 票反对、0 票弃权的结果，审议通过了《关于 2023 年半年度募集资金存放与使用情况的专项报告》 （三）会议以 3 票同意、0 票反对、0 票弃权的结果，审议通过了《关于 2023 年上半年计提资产减值准备的公告》 一、监事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）第八届监事会第七次会议于 2023 年 8 月 18 日以邮件的方式发出通知，于 2023 年 8 月 28 日以现场加通讯表 决的方式召开，其中以通讯表决方式参加会议的监事为张连春女士、汪军先生。 会议由监事会主席许国汉先生主持，会议应参加表决的监事 3 人，实际参加表决 的监事 3 人。会议的召开符合《公司法》和《公司章程》的相关规定，会议合法 有效。 二、监事会会议审议情况 经全体监事认真审议，会议以投票表决的方式形成以下决议： （一）会议以 3 票同意、0 票反对、0 票弃权的结果，审议通过了《公司 2023 年半年度报告及其摘要》 经审核，监事会认为：公司董事会编制和审核 ...

独立董事独立意见 亿帆医药股份有限公司 独立董事关于对控股股东及其他关联方资金占用和公司 对外担保情况的专项说明和独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》及深证证券交易所《上市公司自律监管指引第 1 号——主板上市 公司规范运作》等规定和国家法律法规及公司制度赋予独立董事的职责，我们作 为公司的独立董事，对公司 2023 年上半年对外担保情况以及与关联方的资金往 来情况进行了认真负责的核查，并发表以下独立意见： 经认真核查，公司认真贯彻执行国家法律法规及规定，报告期内没有发生为 公司的股东、股东的控股子公司、股东的附属企业及本公司持股 50%以下的其他 关联方、任何非法人单位或个人提供担保。 报告期末，公司实际对外担保余额为321,689.39万元，占期末归属上市公司 净资产的35.82%，均为公司与全资子公司、控股子公司或全资子公司之间的相互 担保。公司及控股子公司未对合并报表范围外的单位提供担保，也无逾期担保累 计金额、涉及诉讼的担保金额及因担保被判决败诉而应承担的损失金额。公司对 外担保履行了必要的决策程序，符合中国证监会和深圳证券交易所关于上市公 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2023-055 亿帆医药股份有限公司 关于2023年上半年计提资产减值准备的公告 二、本次计提资产减值准备的总体情况 2023 年上半年，公司对存在减值迹象的资产，包括存货、应收款项计提资产 减值准备 5,286.33 万元，明细如下表： 单位：万元 | 项目 | 资产名称 | 2023 年上半年计提资 | 占 2022 | 年度经审计净利 | | --- | --- | --- | --- | --- | | | | 产减值准备金额 | | 润的比例 | | 信用减值损失 | 应收款项—应收账款及票据 | 3,371.13 | | 17.62% | | | 应收款项—其他应收款 | 355.43 | | 1.86% | | | 小计 | 3,726.56 | | 19.48% | | 资产减值损失 | 存货 | 1,559.77 | | 8.15% | | 项目 | 资产名称 | 2023 年上半年计提资 | 占 2022 | 年度经审计净利 | | --- | --- | --- | --- | --- | | | | 产减值准备金额 | | 润的比 ...

亿帆医药股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公 司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》和深圳证券交易 所（以下简称"深交所"）印发的《上市公司自律监管指引第 1 号—主板上市公 司规范运作》以及《上市公司自律监管指南第 2 号——公告格式》的相关规定， 亿帆医药股份有限公司（以下简称"公司"、"本公司"或"亿帆医药"）现将 2017 年非公开发行股票募集资金截至 2023 年 6 月 30 日存放与使用情况作如下 专项说明。 一、募集资金基本情况 1 | 项目 | 募集资金发生额 | | --- | --- | | 其中：存放于银行募集资金专户 | 1,769.80 | | 现金管理 | 0.00 | | 补充流动资金 | 55,000.00 | 二、募集资金存放和管理情况 （一）募集资金管理情况 为了规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权 益，本公司按照《公司法》、《 ...

亿帆医药股份有限公司 | | 辽宁亿帆药业有限公司 | 全资子公司 | 其他应收款 | 9,935.54 | 2,068.09 | 84.17 1,488.28 10,599.52 往来款 | | | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 合肥亿帆医药有限公司 | 全资子公司 | 其他应收款 | | 11,680.01 | | 5,644.03 | 6,035.98 往来款 | 非经营性往来 | | | 合肥亿帆生物制药有限公司 | 全资子公司 | 其他应收款 | 61,791.65 | 36,457.12 | 527.23 38,108.45 60,667.55 往来款 | | | 非经营性往来 | | | 欧芬迈迪（北京）生物技术有限公司 | 全资子公司 | 其他应收款 | 200.00 | | | | 200.00 往来款 | 非经营性往来 | | | 亿帆医药研究院（北京）有限公司 | 全资子公司 | 其他应收款 | 5,773.45 | 550.97 | 38.03 | 2,246.14 ...